Summary
Functional PET imaging using a PARP inhibitor (PARPi) analog may serve as an early, dynamic biomarker of response to PARPi therapy in high-grade serous ovarian cancer. Clinically, this could help to rapidly identify PARPi nonresponders, thereby maximizing efficacy and avoiding toxicities of futile treatments.
This content is only available via PDF.
©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.